SF
ELTX icon

Summit Financial’s Elicio Therapeutics ELTX Stock Holding History

Summit Financial’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$107K Hold
10,010
– – ﹤0.01% 1380
2025
Q4 		$79.7K Buy
+10,010
New +$90.8K ﹤0.01% 1276

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Summit Financial's ELTX Position: Q1 2026 in Review

Summit Financial held its Elicio Therapeutics (ELTX) position steady in Q1 2026 at 10,010 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #1380.

Summit Financial first reported a position in ELTX in Q4 2025 and has held it in 2 quarters since. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

  • Summit Financial held 10,010 shares of Elicio Therapeutics worth $107K as of Q1 2026.
  • Summit Financial left its Elicio Therapeutics share count unchanged in Q1 2026.
  • Elicio Therapeutics made up ﹤0.01% of Summit Financial's portfolio in Q1 2026, its #1380 holding.
  • Summit Financial first reported a position in Elicio Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on Summit Financial's 13F filing for Q1 2026, filed 15 May 2026.